We are live on ! Find out more
VIA

Virtus Investment Advisers Portfolio holdings

AUM $363M
1-Year Est. Return 34.89%
This Fund
S&P 500
This Quarter Est. Return
+9.26%
1 Year Est. Return
+34.89%
3 Year Est. Return
+131.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$296M
AUM Growth
-$72M
Cap. Flow
-$84.2M
Cap. Flow %
-28.48%
Top 10 Hldgs %
6.88%
Holding
509
New
39
Increased
197
Reduced
202
Closed
70

Top Buys

Rank Stock Value
1
CEG icon
Constellation Energy
CEG
+$1.64M
2
VEEV icon
Veeva Systems
VEEV
+$1.51M
3
CSCO icon
Cisco
CSCO
+$1.5M
4
FOXA icon
Fox Class A
FOXA
+$1.48M
5
DASH icon
DoorDash
DASH
+$1.48M

Top Sells

Rank Stock Value
1
VABS icon
Virtus Newfleet ABS/MBS ETF
VABS
+$32.2M
2
VSHY icon
Virtus Newfleet Short Duration High Yield Bond ETF
VSHY
+$24.6M
3
SEIX icon
Virtus SEIX Senior Loan ETF
SEIX
+$19M
4
SMC
Summit Midstream
SMC
+$3.67M
5
JNK icon
State Street SPDR Bloomberg High Yield Bond ETF
JNK
+$2.09M

Sector Composition

Rank Sector Weight
1 Financials 33.24%
2 Healthcare 17.43%
3 Technology 12.41%
4 Industrials 9.1%
5 Consumer Discretionary 4.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RYTM icon
201
Rhythm Pharmaceuticals
RYTM
$7.96B
$446K 0.15%
7,052
+606
+9% +$37.1K
KNSA icon
202
Kiniksa Pharmaceuticals
KNSA
$5.93B
$443K 0.15%
16,026
-1,802
-10% -$45.9K
LGND icon
203
Ligand Pharmaceuticals
LGND
$6.36B
$441K 0.15%
3,883
+721
+23% +$77.1K
ACAD icon
204
Acadia Pharmaceuticals
ACAD
$5.03B
$441K 0.15%
20,441
-363
-2% -$6.75K
TVTX icon
205
Travere Therapeutics
TVTX
$5.78B
$440K 0.15%
29,745
+9,699
+48% +$161K
GILD icon
206
Gilead Sciences
GILD
$165B
$440K 0.15%
3,966
+46
+1% +$4.9K
TARS icon
207
Tarsus Pharmaceuticals
TARS
$2.84B
$440K 0.15%
10,852
+3,827
+54% +$172K
AXSM icon
208
Axsome Therapeutics
AXSM
$10.9B
$437K 0.15%
4,183
+377
+10% +$39.9K
ROIV icon
209
Roivant Sciences
ROIV
$26.2B
$437K 0.15%
38,744
+8,525
+28% +$92.4K
KRYS icon
210
Krystal Biotech
KRYS
$9.66B
$435K 0.15%
3,167
+1,099
+53% +$161K
DAWN
211
DELISTED
Day One Biopharmaceuticals
DAWN
$432K 0.15%
66,427
+38,397
+137% +$264K
VRTX icon
212
Vertex Pharmaceuticals
VRTX
$126B
$430K 0.15%
966
+193
+25% +$88.9K
AGIO icon
213
Agios Pharmaceuticals
AGIO
$1.93B
$428K 0.14%
12,881
+3,473
+37% +$105K
TGTX icon
214
TG Therapeutics
TGTX
$7.62B
$428K 0.14%
11,892
+195
+2% +$7.26K
BMRN icon
215
BioMarin Pharmaceuticals
BMRN
$12.4B
$426K 0.14%
7,758
+2,342
+43% +$138K
PTCT icon
216
PTC Therapeutics
PTCT
$6.12B
$426K 0.14%
8,717
+1,134
+15% +$53.8K
PHAT icon
217
Phathom Pharmaceuticals
PHAT
$692M
$425K 0.14%
44,306
-658
-1% -$3.64K
DVAX
218
DELISTED
Dynavax Technologies
DVAX
$424K 0.14%
42,730
+15,094
+55% +$159K
HALO icon
219
Halozyme
HALO
$12.2B
$424K 0.14%
8,148
+643
+9% +$36.6K
BIIB icon
220
Biogen
BIIB
$30.7B
$422K 0.14%
3,359
+1,048
+45% +$131K
HRMY icon
221
Harmony Biosciences
HRMY
$2.24B
$421K 0.14%
13,333
+2,065
+18% +$66.4K
LEGN icon
222
Legend Biotech
LEGN
$4.01B
$416K 0.14%
11,722
+1,606
+16% +$52K
FOLD
223
DELISTED
Amicus Therapeutics
FOLD
$413K 0.14%
72,025
+36,655
+104% +$237K
RARE icon
224
Ultragenyx Pharmaceutical
RARE
$2.55B
$411K 0.14%
11,311
+3,656
+48% +$132K
GERN icon
225
Geron
GERN
$949M
$402K 0.14%
284,868
+193,281
+211% +$274K
7 8
9
10 11

Similar funds

RC
Reik & Co New York $363M AUM 3.03% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
HS
HighVista Strategies Boston, Massachusetts $362M AUM 230.96% 1-Year Est. Return
SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

Virtus Investment Advisers's Q2 2025 Portfolio in Review

As of Q2 2025, Virtus Investment Advisers held 509 positions worth $296M, down 20% from $368M the previous quarter. Its ten largest holdings account for 6.9% of the portfolio.

Virtus Investment Advisers withdrew a net $84.2M in Q2 2025, closing 70 positions and reducing 202 holdings. Its most notable exit was Virtus Newfleet ABS/MBS ETF, an estimated $32.2M position sold in full.

By sector, the portfolio is most concentrated in Financials at 33% of assets, up from 24% a quarter earlier, followed by Healthcare and Technology.

Against the trend, Virtus Investment Advisers opened a new position in Constellation Energy worth $2.01M.

  • Virtus Investment Advisers's largest Q2 2025 buy was Constellation Energy: 6,213 shares worth $2.01M.
  • Virtus Investment Advisers added most to Amgen in Q2 2025, an estimated $1.45M increase.
  • Virtus Investment Advisers's biggest Q2 2025 reduction was EOG Resources, cutting an estimated $1.23M.
  • Virtus Investment Advisers fully exited Virtus Newfleet ABS/MBS ETF in Q2 2025, selling an estimated $32.2M.
  • Virtus Investment Advisers's ten largest holdings make up 6.9% of its $296M portfolio in Q2 2025.
  • Virtus Investment Advisers opened 39 new positions and closed 70 in Q2 2025.
  • Virtus Investment Advisers's portfolio value fell 20% quarter-over-quarter to $296M.

Based on Virtus Investment Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.